Total Payments
$1,982
2024 Payments
$46.01
Companies
23
Transactions
104
Medicare Patients
1,325
Medicare Billing
$382,729
Payment Breakdown by Category
Food & Beverage$1,912 (96.5%)
Education$69.84 (3.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,912 | 100 | 96.5% |
| Education | $69.84 | 4 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $446.49 | 23 | $0 (2021) |
| AbbVie Inc. | $391.30 | 20 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $211.26 | 15 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $136.78 | 7 | $0 (2022) |
| Abbott Laboratories | $92.86 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $89.83 | 6 | $0 (2018) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $78.91 | 1 | $0 (2017) |
| Allergan, Inc. | $70.71 | 4 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $64.37 | 3 | $0 (2020) |
| Ascensia Diabetes Care US Inc. | $59.70 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46.01 | 2 | Lilly USA, LLC ($30.40) |
| 2023 | $44.95 | 2 | AbbVie Inc. ($44.95) |
| 2022 | $295.38 | 15 | ABBVIE INC. ($179.12) |
| 2021 | $247.82 | 16 | AbbVie Inc. ($167.23) |
| 2020 | $271.46 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($70.63) |
| 2019 | $253.75 | 10 | Abbott Laboratories ($92.86) |
| 2018 | $421.84 | 22 | Novo Nordisk Inc ($235.63) |
| 2017 | $400.73 | 23 | Novo Nordisk Inc ($93.54) |
All Payment Transactions
104 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Respiratory | ||||||
| 06/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $30.40 | General |
| Category: Diabetes | ||||||
| 03/17/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: NEUROSCIENCE | ||||||
| 02/03/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $31.51 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: NEUROSCIENCE | ||||||
| 09/15/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: PRIMARY CARE | ||||||
| 06/28/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: NEUROSCIENCE | ||||||
| 06/16/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: NEUROSCIENCE | ||||||
| 06/14/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/03/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/24/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: NEUROSCIENCE | ||||||
| 04/28/2022 | Takeda Pharmaceuticals U.S.A., Inc. | VYVANSE (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: NEUROSCIENCE | ||||||
| 03/11/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/04/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: NEUROSCIENCE | ||||||
| 02/10/2022 | Takeda Pharmaceuticals U.S.A., Inc. | VYVANSE (Drug) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: NEUROSCIENCE | ||||||
| 02/04/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: NEUROSCIENCE | ||||||
| 01/15/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: NEUROSCIENCE | ||||||
| 01/14/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: NEUROSCIENCE | ||||||
| 01/07/2022 | Takeda Pharmaceuticals U.S.A., Inc. | VYVANSE (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: NEUROSCIENCE | ||||||
| 12/09/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $9.84 | General |
| Category: NEUROSCIENCE | ||||||
| 08/20/2021 | Takeda Pharmaceuticals U.S.A., Inc. | VYVANSE (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: NEUROSCIENCE | ||||||
| 08/06/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: NEUROSCIENCE | ||||||
| 08/05/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.02 | General |
| Category: NEUROSCIENCE | ||||||
| 06/05/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: NEUROSCIENCE | ||||||
| 04/09/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 224 | 1,037 | $148,700 | $94,210 |
| 2022 | 5 | 322 | 1,172 | $146,500 | $80,418 |
| 2021 | 8 | 403 | 1,392 | $186,275 | $113,578 |
| 2020 | 8 | 376 | 1,457 | $195,870 | $94,523 |
Total Patients
1,325
Total Services
5,058
Medicare Billing
$382,729
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 148 | 763 | $114,450 | $74,897 | 65.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 274 | $34,250 | $19,313 | 56.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 142 | 760 | $95,000 | $52,957 | 55.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 129 | 292 | $43,800 | $26,380 | 60.2% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 12 | 14 | $2,100 | $623.18 | 29.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 25 | 38 | $1,520 | $434.28 | 28.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 14 | 68 | $4,080 | $23.71 | 0.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 164 | 535 | $80,250 | $52,124 | 65.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 146 | 643 | $80,375 | $48,611 | 60.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 17 | 110 | $13,750 | $6,717 | 48.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 18 | $4,950 | $3,063 | 61.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $2,420 | $1,346 | 55.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 17 | 21 | $2,730 | $1,286 | 47.1% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 16 | 30 | $1,200 | $360.60 | 30.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 16 | 24 | $600.00 | $72.00 | 12.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 158 | 525 | $78,750 | $40,633 | 51.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 107 | 533 | $66,625 | $29,805 | 44.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 22 | 266 | $33,250 | $15,608 | 46.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 22 | 33 | $9,075 | $5,446 | 60.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 21 | 36 | $4,680 | $2,140 | 45.7% |
| G0180 | Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implem | Office | 2020 | 11 | 12 | $1,800 | $515.93 | 28.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 16 | 26 | $1,040 | $297.16 | 28.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 19 | 26 | $650.00 | $77.64 | 11.9% |
About Dr. William Sarantos, M.D
Dr. William Sarantos, M.D is a Internal Medicine healthcare provider based in River Forest, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023192671.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Sarantos, M.D has received a total of $1,982 in payments from pharmaceutical and medical device companies, with $46.01 received in 2024. These payments were reported across 104 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($1,912).
As a Medicare-enrolled provider, Sarantos has provided services to 1,325 Medicare beneficiaries, totaling 5,058 services with total Medicare billing of $382,729. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location River Forest, IL
- Active Since 10/24/2006
- Last Updated 07/09/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023192671
Products in Payments
- UBRELVY (Drug) $253.42
- VYVANSE (Drug) $189.80
- Tresiba (Drug) $184.76
- VRAYLAR (Drug) $161.71
- Victoza (Drug) $139.45
- ENTRESTO (Drug) $136.78
- Supera peripheral stent system (Device) $92.86
- ELIQUIS (Drug) $89.83
- Ozempic (Drug) $86.72
- LifeVest (Device) $78.91
- XARELTO (Drug) $64.37
- LYRICA (Drug) $45.08
- Amitiza (Drug) $38.29
- Xtampza ER (Drug) $36.75
- TOUJEO (Drug) $35.71
- QULIPTA (Drug) $32.62
- MOUNJARO (Drug) $30.40
- LINZESS (Drug) $28.50
- Saxenda (Drug) $24.74
- AIRSUPRA (Drug) $15.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in River Forest
Dr. Sandesh Kuchipudi, M.d, M.D
Internal Medicine — Payments: $4,802
Internal Medicine $4,802
Dr. Dhana Ganesan, Md, MD
Internal Medicine — Payments: $473.47
Internal Medicine $473.47
Teresa Mckenzie, Md, MD
Internal Medicine — Payments: $233.55
Internal Medicine $233.55
Dr. Terrie Weir, Md, MD
Internal Medicine — Payments: $170.26
Internal Medicine $170.26
Mary Schraufnagel, Md, MD
Internal Medicine — Payments: $96.13
Internal Medicine $96.13
Raymond Mcdonald, Md, MD
Internal Medicine — Payments: $88.77
Internal Medicine $88.77